Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®.
Malvern, PA, April 2, 2019
Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) and PROMISEB® Topical Cream in the United States from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma LLC.
Encore Dermatology Inc. Announces Results From Pivotal Study Evaluating Impoyz™ (clobetasol propionate) Cream, 0.025% for the Treatment of Moderate to Severe Plaque Psoriasis
Malvern, PA, January 30, 2019
The announcement was made today, at the 15th annual Maui Derm Conference, that Impoyz Cream demonstrated efficacy early, with 14.2% of Impoyz patients achieving treatment success at day 8 versus 1.6% in the vehicle group. Treatment success was achieved when subjects received a “clear” or “almost clear” assessment, marking at least a 2-grade improvement from their baseline assessment. Efficacy continued during the second week of treatment with 30% of subjects in the Impoyz group achieving treatment success compared to only 9% in the vehicle group by day 15.
Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz™ (clobetasol propionate) Cream, 0.025% Compared to Temovate® (clobetasol propionate) Cream, 0.05%
Malvern, PA, November 27, 2018
Encore Dermatology, Inc. today announced the publication of a Phase 2, open-label study in SKIN The Journal of Cutaneous Medicine. Subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temovate® (clobetasol propionate) Cream, 0.05% (56.3 vs 152.5 pg/mL, P=0.014).
Encore Dermatology Inc. Announces the launch of IMPOYZTM (clobetasol propionate) Cream, 0.025%, a newly formulated high-potency topical corticosteroid
Malvern, PA, May 1, 2018
Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%
Malvern, PA, January 17, 2017
Encore Dermatology Inc., a privately held dermatology
company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05%
in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the
relief of the inflammatory and pruritic manifestations of corticosteroid-responsive
Encore Dermatology, Inc. Announces Launch of HylatopicPlus® Lotion
Malvern, PA, Oct. 13, 2016
Encore Dermatology, Inc., a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus® Lotion in a convenient 14 oz. bottle with pump dispenser.
Encore Dermatology, Inc., A New Specialty Dermatology Company
Malvern, PA, May 18, 2015
Encore Dermatology, Inc. announced today that it has begun to commercialize HylatopicPlus® and Tetrix®, two highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates.